CA
KALV

Cliff Asness’s KalVista Pharmaceuticals KALV Stock Holding History

Cliff Asness’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-37,572
Closed -$756K – 3935
2026
Q1 		$756K Buy
37,572
+12,906
+52% +$208K ﹤0.01% 2912
2025
Q4 		$398K Sell
24,666
-19,940
-45% -$264K ﹤0.01% 3033
2025
Q3 		$543K Sell
44,606
-2,807
-6% -$38.8K ﹤0.01% 2777
2025
Q2 		$536K Sell
47,413
-8,562
-15% -$105K ﹤0.01% 2583
2025
Q1 		$646K Buy
+55,975
New +$571K ﹤0.01% 2278
2024
Q4 		– Sell
-12,354
Closed -$143K – 2906
2024
Q3 		$143K Buy
+12,354
New +$155K ﹤0.01% 2619
2024
Q2 		– Sell
-10,538
Closed -$125K – 2639
2024
Q1 		$125K Buy
+10,538
New +$140K ﹤0.01% 2316
2023
Q2 		– Sell
-21,848
Closed -$172K – 2235
2023
Q1 		$172K Sell
21,848
-72,436
-77% -$541K ﹤0.01% 2075
2022
Q4 		$637K Buy
+94,284
New +$505K ﹤0.01% 1724

Other funds holding KALV

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Cliff Asness's KALV Position: Q2 2026 in Review

Cliff Asness sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 37,572 shares — an estimated $756K sold.

Cliff Asness first reported a position in KALV in Q4 2022 and held it in 9 quarters. The position peaked at $756K in Q1 2026. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.

  • Cliff Asness reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Cliff Asness sold 37,572 KalVista Pharmaceuticals shares in Q2 2026, an estimated $756K.
  • Cliff Asness first reported a position in KalVista Pharmaceuticals in Q4 2022 and held it in 9 quarters.
  • Cliff Asness's KalVista Pharmaceuticals position peaked at $756K in Q1 2026.
  • 1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.